* GENFIT *
1999 - North-Picardie
Lille
www.genfit.com Discovery, Drugs
Key words: Cardiometabolic diseases, Dyslipidemia, Diabetes
Mission: to discover new treatments for major cardiovascular, metabolic and inflammatory diseases, as well as age-linked neurodegenerative disorders
Clients: Pharmaceutical industry
contact@genfit.com
Identity| TYPE/MANAGEMENT/INVESTORS | FINANCES/STATUS | | Start-up |
Managing Dir.: Mouney (Jean-François) [co-founder, born 1955, Sup de Co (Paris), ex-M&M]
Sc.Dir.: Hum (Dean W.) [Ph.D. biochemistry]
Fin.Dir.: Huitorel (Nathalie) [Sup de Co (Lille), ex-MS Composites, Finuchem]
BusDev:
Financers: Finorpa, Nord Cration, BP Création, Public | Turnover (M€) : 9.9 (2006)
Total funding (M€) : n.a.
Last funding (M€) : 15.0
Focus : Cardiovasc
Position : Clinical
Company confirm : none |
History | DATE | MILESTONE | TYPE | TIME | | 2008 .06 | Financing (no interest loan) : 7.1 M€, by Oseo for IT-Diab programme (drug and diag) with Genoway, SpiBio, Roowin and Academic Institutions, over 5 years | DEBT | [9 years] |
| 2008 .04 | Management crisis : direct conflict between 2 co-founders, Jean-François Mouney, CEO and Jean-Charles Fruchart, President of Supervisory Board (dismissed) | ORG | [9 years] |
| 2006 .12 | Listing on Alternext : 15.0 M€ | PBO | [7 years] |
| 2006 .05 | Clinical trial (phase II) for first lead, GFT14 (beginning) | CLIN | [7 years] |
| 2003 .00 | Set-up of international offices in Cambridge (USA) | ORGC | [4 years] |
| 2000 .03 | Seed financing : 2 M€, by UCB, Aventis, Sanofi-Synthelabo, Merck-Lipha, Finorpa, Nord Création, BP Création | SFIN | [1 year] |
| 1999 .09 | Company founded by Prof. Jean-Charles Fruchart (born 1945), Jean-François Mouney, Prof. Bart Staels, Florence Séjourné | ORGF | [0 year] | Actualisation / Updating: 31-Oct-2008 |
|
